Skip to main content
. Author manuscript; available in PMC: 2011 Feb 15.
Published in final edited form as: Cancer. 2010 Feb 15;116(4 Suppl):1134–1145. doi: 10.1002/cncr.24802

Figure 6.

Figure 6

Veltuzumab bsMAb pretargeted 90Y-hapten-peptide improves therapeutic response compared to directly radiolabeled 90Y-veltuzumab. Nude mice bearing s.c. Ramos tumors were treated with the MTD of 90Y-veltuzumab (0.13 mCi/0.05 mg) or a pretargeting procedure using a humanized, recombinant bispecific antibody containing 2 veltuzumab Fab fragments and one anti-hapten Fab fragment capable of binding the 90Y-hapten peptide. 0.5 or 0.7 mCi of the pretargeted 90Y-hapten-peptide only result in ~50–70% loss in WBC that recovers in several weeks, whereas 0.13 mCi of 90Y-veltuzumab causes >90% loss in WBC that requires 7 weeks to recover. Growth curves and the subsequent survival curve shows the improved responses in the pretargeted animals with the ability to completely ablate 9/10 tumors at the 0.7 mCi 90Y-hapten-peptide dose.